Large Clinical Trial Confirms Efficacy Of Sanofi’s Dengue Vaccine

News outlets report on French drugmaker Sanofi’s announcement that its experimental dengue vaccine has reduced disease cases in a large clinical trial.

Bloomberg News: Sanofi Dengue Vaccine Works on All Four Types in Study
“Sanofi’s experimental vaccine against dengue protected children with all four types of the mosquito-borne illness in a clinical test, a stronger result than shown in a smaller study this year…” (Serafino, 9/3).

Reuters: Final trial confirms efficacy of Sanofi’s dengue vaccine
“French drugmaker Sanofi, developing the first vaccine against dengue fever, said its product reduced disease cases by 60.8 percent in a large final clinical trial. Sanofi has invested more than 1.3 billion euros ($1.7 billion) in the project, undertaking two decades of research on the world’s fastest-growing tropical disease…” (Huet, 9/3).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.